|Bid||81.42 x 2900|
|Ask||81.43 x 800|
|Day's Range||81.05 - 81.77|
|52 Week Range||62.38 - 87.07|
|Beta (3Y Monthly)||0.33|
|PE Ratio (TTM)||25.72|
|Forward Dividend & Yield||2.20 (2.70%)|
|1y Target Est||N/A|
With earnings surprise in cards, the healthcare sector is expected to witness earnings growth of 1.7% in the second quarter, suggesting continued outperformance for healthcare ETFs.
Investors will focus on regular top- and bottom-line numbers along with updates on the Celgene merger, when Bristol-Myers (BMY) reports second-quarter results.
Bristol-Myers (BMY), Ono Pharmaceutical and Bayer ink a collaboration deal to evaluate the combination of Opdivo plus Stivarga for treating micro-satellite stable metastatic colorectal cancer.
J&J (JNJ) and Novartis (NVS) set the earnings season in motion for the pharma space. FDA approves Merck's (MRK) new combination antibacterial injection, Recarbrio.
Mallinckrodt (MNK) halts its phase IIB study, assessing the efficacy and safety of Acthar Gel as an investigational treatment for amyotrophic lateral sclerosis.
Merck & Co., Inc. (NYSE: MRK ) continues to find success with its product pipeline, with another of its treatment options receiving FDA approval. Merck announced Wednesday that the FDA OK'd RECARBIO, ...
Shares of Merck & Co Inc. ticked up 0.5% in premarket trade Wednesday after the company said the U.S. Food and Drug Administration had approved its antibacterial Recarbrio injection for use in treating complicated urinary tract infections. The drug is also approved for use in adult patients who have limited options for the treatment of complicated intra-abdominal infections caused by certain bacteria. Merck said it expects to make the drug available later this year. Shares of Merck have gained 6.8% so far this year through Wednesday, while the S&P 500 has gained 19.8%.
The U.S. Food and Drug Administration has approved Merck & Co Inc's combination treatment for complicated forms of urinary tract and abdominal infections, the drugmaker said on Wednesday. Recarbrio, approved for patients over 18 years of age, is a combination of a previously approved antibiotic imipenem-cilastatin and Merck's relebactam. Patients with urinary tract infections can develop complications if appropriate doses of the right antibiotics are not administered.
Investors will focus on regular top- and bottom-line numbers along with pipeline updates when Novartis (NVS) reports second-quarter results.
Glaxo's (GSK) phase III study evaluating Zejula as a first-line maintenance therapy in patients with ovarian cancer meets the primary endpoint.
The Zacks Analyst Blog Highlights: Cisco, Home Depot, Merck, Humana and Public Service Enterprise
J&J (JNJ) beats estimates for both earnings and sales in the second quarter of 2019 and raises 2019 guidance for operational sales growth for the second time this year.